Image Not FoundImage Not Found

  • Home
  • Business
  • Astellas Pharma Seals $5.9 Billion Deal with Iveric Bio
Image

Astellas Pharma Seals $5.9 Billion Deal with Iveric Bio

Astellas Pharma, a Japanese pharmaceutical company, has announced the completion of its acquisition of IVERIC Bio Inc. The deal was made through Berry Merger Sub, Inc., a wholly-owned subsidiary of Astellas US Holding, Inc. for 5.9 billion dollars.

Iveric Bio is an American biopharmaceutical company that specializes in developing treatments and therapies to prevent vision loss from retinal diseases, such as age-related macular degeneration (AMD). Their portfolio includes several pipeline drugs and products, which are currently being developed or awaiting approval by regulatory authorities around the world, including Europe and Japan.

This move will strengthen Astellas’ presence in ophthalmology with Iveric’s existing product portfolio while also providing them access to new technologies and resources that can be used to develop innovative treatments for AMD patients worldwide. It will also help them expand their reach into other markets where they may not have had much presence before this acquisition took place, such as Europe and Asia Pacific regions, where there is a high demand for eye care solutions due to aging populations in those areas.

The combined entity will now create better opportunities for both companies moving forward as they strive towards creating more effective treatments against retinal diseases like AMD across global markets.

Read more at Reuters
Image Not Found

Discover More

Pulsar Fusion's "Sunbird" Rocket: Nuclear-Powered Leap Towards Faster Mars Travel
Global Markets Tumble as Trump Tariffs Trigger Tech Selloff and Trade War Fears
Trump's 50% Tariff Threat: US-China Trade War Escalates with 2025 Ultimatum
Nintendo Switch 2: Game-Key Cards Revolutionize Digital and Physical Game Sales
Trending Now: From Baseball Bats to AI - How Tech, Entertainment, and Lifestyle Intersect
From Corporate Grind to Island Paradise: American Couple's Thai Business Adventure
Personal Loan Rates 2023: How Credit Scores Impact Your Borrowing Power
Tesla's Autopilot Under Fire: Motorcycle Deaths Spark Safety Concerns and Regulatory Debate
Crypto Scams Surge: Experts Urge Caution as Losses Hit Billions in 2022